Recently, their application has been expanded to include multiple cancers and has extended beyond BRCA1/2 mutations containing tumors to include a broader range of genetic mutations, involving DNA repair and defects involving homologous repair pathway [4,6], such as BRIP1, RAD51C, RAD51D, ATM, PALB2, CHEK2, etc. This evidence concerns the gene BRCA1 and cancer.